MTX-001 for Bipolar Depression

Repurposed drugs combination identified using our biomarkers research.

To be developed as an add-on to current treatments for bipolar depression.

May not only improve efficacy, but also lower side-effects of existing medications and usual co-morbidities (cardiac, metabolic syndrome).